Kirkland Advises PathGroup on Majority Investment from GTCR
Kirkland & Ellis advised PathGroup, a premier provider of anatomic, clinical, molecular and digital pathology services in the United States, on a majority investment in the company from GTCR, a leading private equity firm, in partnership with founder and CEO Ben Davis, MD and the PathGroup management team, who have made a substantial reinvestment in PathGroup.
The Kirkland team was led by corporate partner Adam Wexner and associates Kevin Stocks, Matthew Brandys and Zackary Theo, with support from corporate partner Benjamin Clinger, tax partner Tom Evans and associate Ruth Thomson, healthcare partners Dennis Williams, Chad Ehrenkranz and Melesa Freerks and associates Kelly McGinnis and Brittany Strandell, capital markets partner Bob Goedert and associate Monica Norzagaray, debt finance partner Michelle Kilkenney and associate Ellen Horne, technology & IP transactions partner Dan Lewis and associate Jake Lipnik, real estate partner Josh Faulkner and associate David Arbus, executive compensation partner Michael Falk and associates Deidre Kalenderian and Rebecca Arnall, employee benefits partner Alexandra Mihalas and associate Ted Brown, labor and employment partner Michael Schulman and associate Kayla Davis, environmental transactions partner James Dolphin and associate Michelle Sliwinski and antitrust partners Mike Thorpe, Matthew Reilly and Stephanie Greco and associates Kelsey Laugel and Emily Hsu.
